Key result
Positive genotype shows no link to increased ventricular arrhythmias in sports-active HCM.
Why the study?
The impact of genotype on arrhythmic risk in sports-active hypertrophic cardiomyopathy patients remains unclear.
Does genotype-positive status increase the risk of ventricular arrhythmic events in sports-active patients with hypertrophic cardiomyopathy compared to genotype-negative status?
Cohort (n=59)
No
Does genotype-positive status increase the risk of ventricular arrhythmic events in sports-active patients with hypertrophic cardiomyopathy compared to genotype-negative status?
In sports-active patients with hypertrophic cardiomyopathy, genotype status does not appear to significantly discriminate individual risk for ventricular arrhythmias or cardiovascular events.
Answers are grounded in this paper and cite their sources.
Genotype should not yet guide arrhythmic risk assessment in sports-active HCM; leaves open need for prospective validation in larger cohorts.
Aims The impact of genotype on arrhythmic risk in sports-active hypertrophic cardiomyopathy (HCM) patients remains unclear. We compared outcomes between genotype-positive (G+) and genotype-negative (G-) athletes with HCM. Methods In this retrospective study, HCM patients actively engaged in sports underwent standardized baseline evaluation and follow-up. The primary endpoint included sudden cardiac death/arrest (SCD/SCA), appropriate implantable cardiovert-defibrillator (ICD) therapy, sustained/non-sustained ventricular tachycardia (SVT/NSVT). Secondary outcomes included a composite of ventricular arrhythmias, atrial fibrillation, ischemic stroke, and heart-failure hospitalization. Results Fifty-nine patients (age 40 years [23.2-50.0]) were followed for 6.3 years [3.0-12.6]. Twenty-nine participants (49.2%) carried a likely pathogenic or pathogenic variant, most commonly MYBPC3 (44.8%), MYH7 (24.1%) and TNNT2 (17.2%). At inclusion, median sport practice was 6.0 [3.0-10.0] hours-per-week, with 67.8% of competitors. At last follow-up, 88.1% remained active in sports. The ESC 5-years SCD risk score was slightly higher in G+ compared with G- patients (1.87% [1.47-3.67] vs 1.54% [1.24-2.20], p=0.048), but most of the participants were classified as low risk. Ventricular arrhythmias occurred in 20.7% of G+ and 23.3% of G- patients (p=0.807), with similar event–free survival (p=0.685). Most ventricular arrythmias were isolated NSVT (84.6%). Hard ventricular arrhythmic events were limited to two ICD-terminated ventricular fibrillations in G+ patients, one at rest and one during low-intensity exercise. The incidence of the composite secondary CV outcome was comparable between groups (31.0% vs. 33.3%, p=0.850). Conclusions In this exploratory cohort of sport active HCM patients, ventricular arrhythmic and cardiovascular event rates were similar between G+ and G- participants during follow-up.
No takes yet. Share an insight, caveat, or question.
Myon et al. (2026) conducted a cohort in Hypertrophic cardiomyopathy (HCM) in sports-active individuals (n=59). Genotype-positive status vs. Genotype-negative status was evaluated on Composite of ventricular arrhythmic events including sudden cardiac arrest/death, appropriate ICD therapy, sustained ventricular tachycardia, and non-sustained ventricular tachycardia (p=0.807). In sports-active individuals with hypertrophic cardiomyopathy, ventricular arrhythmic event rates were similar between genotype-positive and genotype-negative participants.
Synapse has enriched 10 related papers. Consider them for comparative context: